Hananja

News

European Pre-Eclampsia Project gets FUNDED

E-mail Print PDF

Thursday, February 7th 2013 the Project "ASPRE" submitted to the European Union for funding through the 7th R&D framework was approved for funding with allowed budget of 5.89 million Euro.

Lead by Prof. Nicolaides from Fetal Medicine Foundation, UK the project title is: "Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for Evidence-Based Pre-eclampsia Prevention" . It involves following groups and companies: Hylabs (Israel), Wallac (Finland), Astraia (Germany) and Hananja (Iceland).

Read more...
 

Emerging data presented by USL in San Diego Epilepsy and Neurology meetings 2012 & 2013

E-mail Print PDF

Upsher-Smith Laboratories released a press release on November 26th, 2012 on their committed to the development of new treatments for e.g. epilepsy. They are proud to sponsor emerging data on USL261, its novel formulation of intranasal midazolam, at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, CA, November 30 – December 4, 2012.

Read more...
 

EPILEPTIC SEIZURES: NEW EFFECTIVE TREATMENT IN SIGHT

E-mail Print PDF

Intranasal delivery
Epilepsy is caused by disturbed electrical activity in the brain and has been recognized for at
least 2400 years. It is expressed as a collection of many different types of seizures that vary
widely in severity, appearance, cause, consequence and management. Its most severe form,
status epilepticus, is a neurological emergency that may result in brain damage or death.
Seizures should be treated as soon as possible. From onset of seizures and until the initiation
of the treatment should be as short as possible, to reduce the damage seizures can cause as
well as the risk of morbidity and mortality.

 

 

Read more...
 
Þú ert hér: Home News

Support center

Hananja plc

  • Address: Aflagrandi 7
  • City: 107 Reykjavík, Iceland
  • Tel: (+354) 898-0318
  • Email: sg@hananja.com